Drug Trial Radar · NCT06897930
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Apr 21, 2025
Primary completion
May 1, 2029
Study completion May 1, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Conditions
- Lupus Erythematosus, Systemic
Interventions
AZD0120Biological
Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..
CyclophosphamideDrug
Lymphodepletion - specified dose prior to receiving AZD0120
FludarabineDrug
Lymphodepletion - specified dose prior to receiving AZD0120
Primary outcomes
What the sponsor says the trial is designed to measure.
- PHASE 1B: To evaluate the safety and tolerability of AZD0120 in participants with refractory systemic lupus erythematosus (SLE)Time frame: 2 years
- PHASE 1B: Recommended Phase 2 Dose (RP2D) of AZD0120 in for Phase 2Time frame: 2 years
- PHASE 2: To evaluate the efficacy of AZD0120 in participants with refractory SLETime frame: 2 years
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
San Francisco, California · Recruiting
Research Site
Stanford, California · Withdrawn
Research Site
Tampa, Florida · Withdrawn
Research Site
Atlanta, Georgia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Baltimore, Maryland · Not yet recruiting
Research Site
Bethesda, Maryland · Withdrawn
Research Site
Boston, Massachusetts · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Syracuse, New York · Recruiting
Research Site
Chapel Hill, North Carolina · Recruiting
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Richmond, Virginia · Not yet recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Darlinghurst, Australia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Toronto, Ontario, Canada · Withdrawn
Research Site
Bristol, United Kingdom · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.